Diabetic Macular Edema Vastly Undertreated, Real-World Data Suggest

Source: Medscape

Most patients with newly diagnosed diabetic macular edema (DME) are inadequately treated, according to findings from the American Academy of Ophthalmology's IRIS Registry, as reported in Medscape.

"We found that DME patients are likely undertreated in the real-world setting," said study investigator Jeffrey R. Willis, MD, PhD, from the University of California Davis in Sacramento, who is also employed by Genentech, the study's sponsor. "Even when patients receive anti-VEGF [vascular endothelial growth factor] treatment, they are likely to get a suboptimal number of injections."

The Intelligent Research in Sight (IRIS) registry is the United States' first comprehensive eye disease clinical database. Approximately 70% of ophthalmologists, or about 13,000 physicians, contribute data to the registry.

Read the full article.

Related Content